141 related articles for article (PubMed ID: 22827973)
1. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
Crew KD; Brown P; Greenlee H; Bevers TB; Arun B; Hudis C; McArthur HL; Chang J; Rimawi M; Vornik L; Cornelison TL; Wang A; Hibshoosh H; Ahmed A; Terry MB; Santella RM; Lippman SM; Hershman DL
Cancer Prev Res (Phila); 2012 Sep; 5(9):1144-54. PubMed ID: 22827973
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus.
Joe AK; Schnoll-Sussman F; Bresalier RS; Abrams JA; Hibshoosh H; Cheung K; Friedman RA; Yang CS; Milne GL; Liu DD; Lee JJ; Abdul K; Bigg M; Foreman J; Su T; Wang X; Ahmed A; Neugut AI; Akpa E; Lippman SM; Perloff M; Brown PH; Lightdale CJ
Cancer Prev Res (Phila); 2015 Dec; 8(12):1131-7. PubMed ID: 26471236
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia.
Shanafelt TD; Call TG; Zent CS; LaPlant B; Bowen DA; Roos M; Secreto CR; Ghosh AK; Kabat BF; Lee MJ; Yang CS; Jelinek DF; Erlichman C; Kay NE
J Clin Oncol; 2009 Aug; 27(23):3808-14. PubMed ID: 19470922
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers.
Gee JR; Saltzstein DR; Kim K; Kolesar J; Huang W; Havighurst TC; Wollmer BW; Stublaski J; Downs T; Mukhtar H; House MG; Parnes HL; Bailey HH
Cancer Prev Res (Phila); 2017 May; 10(5):298-307. PubMed ID: 28325826
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.
Nguyen MM; Ahmann FR; Nagle RB; Hsu CH; Tangrea JA; Parnes HL; Sokoloff MH; Gretzer MB; Chow HH
Cancer Prev Res (Phila); 2012 Feb; 5(2):290-8. PubMed ID: 22044694
[TBL] [Abstract][Full Text] [Related]
6. Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer.
Crew KD; Ho KA; Brown P; Greenlee H; Bevers TB; Arun B; Sneige N; Hudis C; McArthur HL; Chang J; Rimawi M; Cornelison TL; Cardelli J; Santella RM; Wang A; Lippman SM; Hershman DL
J Hum Nutr Diet; 2015 Jun; 28(3):272-82. PubMed ID: 24646362
[TBL] [Abstract][Full Text] [Related]
7. The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial.
Dostal AM; Samavat H; Bedell S; Torkelson C; Wang R; Swenson K; Le C; Wu AH; Ursin G; Yuan JM; Kurzer MS
Food Chem Toxicol; 2015 Sep; 83():26-35. PubMed ID: 26051348
[TBL] [Abstract][Full Text] [Related]
8. A two-stage, single-arm, phase II study of EGCG-enriched green tea drink as a maintenance therapy in women with advanced stage ovarian cancer.
Trudel D; Labbé DP; Araya-Farias M; Doyen A; Bazinet L; Duchesne T; Plante M; Grégoire J; Renaud MC; Bachvarov D; Têtu B; Bairati I
Gynecol Oncol; 2013 Nov; 131(2):357-61. PubMed ID: 23988418
[TBL] [Abstract][Full Text] [Related]
9. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
[TBL] [Abstract][Full Text] [Related]
10. Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer.
Henning SM; Wang P; Abgaryan N; Vicinanza R; de Oliveira DM; Zhang Y; Lee RP; Carpenter CL; Aronson WJ; Heber D
Mol Nutr Food Res; 2013 Mar; 57(3):483-93. PubMed ID: 23319439
[TBL] [Abstract][Full Text] [Related]
11. The Minnesota Green Tea Trial (MGTT), a randomized controlled trial of the efficacy of green tea extract on biomarkers of breast cancer risk: study rationale, design, methods, and participant characteristics.
Samavat H; Dostal AM; Wang R; Bedell S; Emory TH; Ursin G; Torkelson CJ; Gross MD; Le CT; Yu MC; Yang CS; Yee D; Wu AH; Yuan JM; Kurzer MS
Cancer Causes Control; 2015 Oct; 26(10):1405-19. PubMed ID: 26206423
[TBL] [Abstract][Full Text] [Related]
12. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
[TBL] [Abstract][Full Text] [Related]
13. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial.
Mielgo-Ayuso J; Barrenechea L; Alcorta P; Larrarte E; Margareto J; Labayen I
Br J Nutr; 2014 Apr; 111(7):1263-71. PubMed ID: 24299662
[TBL] [Abstract][Full Text] [Related]
14. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy.
Henning SM; Wang P; Said JW; Huang M; Grogan T; Elashoff D; Carpenter CL; Heber D; Aronson WJ
Prostate; 2015 Apr; 75(5):550-9. PubMed ID: 25545744
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia.
D'Arena G; Simeon V; De Martino L; Statuto T; D'Auria F; Volpe S; Deaglio S; Maidecchi A; Mattoli L; Mercati V; Musto P; De Feo V
Int J Immunopathol Pharmacol; 2013; 26(1):117-25. PubMed ID: 23527714
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of topical epigallocatechin-3-gallate (EGCG) in patients with breast cancer receiving adjuvant radiotherapy.
Zhao H; Zhu W; Jia L; Sun X; Chen G; Zhao X; Li X; Meng X; Kong L; Xing L; Yu J
Br J Radiol; 2016; 89(1058):20150665. PubMed ID: 26607642
[TBL] [Abstract][Full Text] [Related]
17. Interaction of green tea catechins with breast cancer endocrine treatment: a systematic review.
Yiannakopoulou EC
Pharmacology; 2014; 94(5-6):245-8. PubMed ID: 25471334
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy.
Zhu W; Jia L; Chen G; Zhao H; Sun X; Meng X; Zhao X; Xing L; Yu J; Zheng M
Oncotarget; 2016 Jul; 7(30):48607-48613. PubMed ID: 27224910
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
